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Dear Editor,
A 48-year old patient with known xeroderma pig-
mentosum was referred to our skin cancer unit because of 
the recent development of histopathologically verified 
squamous cell carcinoma (SCC) lymph node metastasis 
on her left supraclavicular region. A whole body PET-CT 
showed additional abdominal and inguinal lymph node 
metastases. Her medical history included, in addition to 
several minimal surgeries of early forms of keratinocyte 
skin cancer, a poorly differentiated cutaneous SCC 
(cSCC) with invasion into the lymphatic vessels on her 
left tight, which was treated with wide surgical excision 5 
years before. Moreover, she suffered from an incipient 
renal insufficiency not requiring current treatment.
On whole body examination, multiple pigmented 
freckles and actinic keratoses but no other forms of skin 
cancer were detected. The supracervical lymph node 
metastasis presented as indurated, infiltrating
plaque, while the other lymph node regions were un-
remarkable on palpation.
Based on these findings, a diagnosis of stage IV cSCC
was made and she was presented at our interdisciplinary
tumour board. Because review of the radiographic images
was suggestive of the risk of an upper venous congestion in
the cervical region, surgical debulking of the cervical
lymph node mass was recommended before systemic
treatment. With regard to the latter, a decision to treat
with the programmed cell death protein 1 (PD-1) antibody
pembrolizumab was made. This was based on the young
age of the patient, her renal comorbidities and recent ev-
idence showing promising results of PD-1 antibodies in
advanced forms of cSCC. After 2 weeks of surgery of the
supraclavicular lymph node metastases, she received 2
milligram (mg) pembrolizumab per kilogram body weight
in a 3-weekly intravenous infusion schedule. The treat-
ment was well tolerated by the patient. After the third
cycle, restaging by whole body PET-CT was performed
showing a significant regression of all metastases (Fig. 1A
and B). Based on the evident partial response, treatment
with pembrolizumab was continued and is still ongoing.
The expression of PD-1, programmed death-ligand 1
(PD-L1) and epidermal growth factor receptor (EGFR)
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2in the cervical lymph node metastasis was analysed by
immunohistochemistry.
Serial sections of the paraffin-embedded core biopsy
material were cut at 2 mm and further processed using a
BenchMark Ultra automated stainer (Roche Ven-
tana). For the particular primary antibodies, the
following procedures were used: PD-L1 (clone 28-8;
Abcam) diluted at 1:100 was incubated for 32 min and
the OptiView DAB detection kit ultra CC1 was used
for 36 min. PD-1 (clone NAT 105; Cell Marque AK)
ready to use incubated for 32 min followed by the
UltraView DAB detection kit ultra CC2 for 44 min.
EGFR (clone 3C6; Roche) ready to use was incubated
for 32 min after antigen retrieval by protease 1 for
8 min. For detection, the UltraViewDAB detection kit
and for counterstaining haematoxylin were used. The
evaluation of immunohistochemistry was performed
semiquantitatively. A weak-to-moderate immunoreac-
tivity for PD-L1 was found in 10%e20% of the tumour
cell and 20%e30% of the lymphocytes (Fig. 2B). A
moderate-to-strong PD-1 immunoreactivity was present
in about 20% of the lymphocytes, whereas the tumour
cells were negative (Fig. 2C). About 70% of the tumour
cells showed a moderate to strong EGFR immunore-
activity (Fig. 2D).
Comment:
Xeroderma pigmentosum (XP) is a rare, autosomal-
recessive transmitted genodermatosis. The basic defect
in XP is in the nucleotide excision repair, leading to
deficient repair of ultra-violet radiationeinduced DNA
damages. As a consequence, patients with XP develop
multiple cutaneous malignancies including non-
melanoma skin cancer and melanoma already at
young age [1,2]. The most important causes of mortality
are due to metastatic melanoma and cSCC.
Because of the rarity of XP-associated stage IV ma-
lignancies, currently, there is no established standard of
care for stage IV melanoma or cSCC.
Inhibition of the PD-1 has achieved a highly effective
antitumour activity in several forms of cancers including
cutaneous melanoma, Merkel cell carcinoma, and more
recently, also in advanced forms of cSCC [2e8].
A review of the literature reveals up to 12 patients
with advanced cSCC treated with pembrolizumab of
whom 11 responded well to treatment (Table 1).
Hauschild et al. were the first to report the use of
the PD-1 antibody pembrolizumab in a patient with
XP, who suffered from metastatic melanoma [2]. They
observed a notable regression of the melanoma
metastases as well as disappearance of other forms of
non-melanocytic skin cancer after 3 months of
treatment.
To the best of our knowledge, our patient is the first
report on the effectiveness of pembrolizumab in a pa-
tient with XP-associated metastatic cSCC. Similar to the
observation by Hauschild et al., we observed a rapid
response to treatment after only three cycles of treat-
ment. However, we did not note any significant
improvement of the pre-existing cutaneous freckles in
our patient. This may be explained by a possible less
Fig. 1. A and B: Pathological lymph nodes para-aortic (A) and complete remission after three circles with pembrolizumab (B).
3immunogenic profile of initial versus advanced forms of
keratinocytic skin cancer.
Notably, immunohistochemistry of the lymph node
metastasis in our patient did not reveal a high expression
of PD-1 or PD-L1 in the tumour, but was mainly
detectable in the infiltrating lymphocytes. In contrast,
the tumour showed high expression of EGFR.
Although Stevenson [4] proved increased PD-1 and
PD-L2 expressions in high-risk cSCC and concluded
that both proteins might function as predictors of
response to treatment, there is considerable discussion
about the role of PD-1 expression as a predictive factor
in melanoma, as both tumours with high and low ex-
pressions respond well to treatment. Our case is in line
Table 1
Summary of all hitherto described cases of locally advanced or metastatic squamous cell carcinoma treated with PD-1 inhibitors.
Reference Sex Location Histological subtype PD-1 inhibitor PD-L1 immunostaining Best overall response
Chang et al. 2016 Male Right temple Moderately to
poorly differentiated
Pembrolizumab Strongly positive in
the primary tumour
Partial response
Falchook et al. 2016 Male Left cheek Not specified REGN2810 Not specified Complete response
Tran et al. 2017
Patient I
Male Right temple Not specified Pembrolizumab Tumour-infiltrating
lymphocytes positive
Partial response
Tran et al. 2017
Patient II
Male Left upper back Not specified Pembrolizumab Not specified Complete response
Tran et al. 2017
Patient III
Male Unknown Unknown Nivolumab Not specified Partial response
Tran et al. 2017
Patient IV
Male Left chin Acantholytic Pembrolizumab Not specified Partial response
Tran et al. 2017
Patient V
Female Left shoulder Moderately
differentiated
Pembrolizumab Not specified Mixed response
Tran et al. 2017
Patient VI
Female Left postauricular Poorly differentiated Pembrolizumab Not specified Progression
Stevenson et al. 2017 Male Right superior forehead Not specified Pembrolizumab Strongly positive in
the primary tumour
Complete response
Hauschild et al. 2017 Male Multiple; caused by
xeroderma pigmentosum
Not specified Pembrolizumab Not specified Partial response
Degache et al. 2017
Patient I
Male Left temple Intermediately
differentiated
Pembrolizumab Not specified Partial response
Degache et al. 2017
Patient II
Male Left cervical Poorly differentiated Pembrolizumab Not specified Partial response
Fig. 2. AeD: Moderately differentiated non-keratinising squamous cell carcinoma surrounded by lymphocytes (biopsy of a lymph node
metastasis; HE staining) (A). PD-L1 immunoreactivity is present in both tumour cells and lymphocytes (B) whereas PD-1 immunore-
activity is only found in lymphocytes (C). The majority of tumour cells show EGFR immunoreactivity (D). Abbreviations: PD-L1,
programmed death-ligand 1.
4with the current observations made in melanoma and
contradicts the assumption that PD-1 expression may be
predictive for treatment response in cSCC. Similarly,
current data also do not support any predictive value of
EGFR expression for response to the EGFR inhibitor
cetuximab in cSCC [5].
In conclusion, the current literature along with our
case suggests that the PD-1 inhibitor pembrolizumab
represents a promising therapy for locally advanced or
metastatic cSCC with or without association with XP.
However, there is the need for prospective clinical trials
with sufficient long-term follow up to better define the
role of PD-1 inhibitors in the systemic treatment of cSCC.
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